In previous studies using HFD animal models, dietary KO ameliorates the hepatic steatosis and dyslipidemia through AMPK activation [36], and the oral gavage improves metabolic alterations in the liver through a modification of lipid synthesis-related gene expressions (i.e., PPARα, SREBP1c, and FAS) [42]. Here, PRKAA1 is linked to fatty liver disease.